Chinese medical company Asclepius Meditec reported on Monday the availability of an environmentally friendly treatment generator AMS-H-03 involving the electrolysis of H2O to produce a mixture of hydrogen and oxygen for inhalation by COVID-19 patients with no side effects.
In a multicentered, open-label clinical trial, titled "Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial", the inhalation of the hydrogen/oxygen mixture prevented the further progression of the disease and, most notably, alleviated the shortness of breath experienced by COVID-19 patients. The results of the research as a treatment for COVID-19 were published in the June 2020 edition of the Journal of Thoracic Disease (JTD).
Asclepius Meditec added that the research and clinical trial was conducted on 44 patients with COVID-19 whose dyspnea could not be ameliorated after regular treatment in 11 hospitals. After three days of continuous use of the hydrogen/oxygen generator, AMS-H-03 , all 44 patients showed significant improvement compared with 46 patients who received the standard regimen of oxygen alone.
According to the company, the hydrogen/oxygen generator AMS-H-03 has received the Class III Medical Device certificate from China's National Medical Products Administration. The AMS-H-03 helps to reduce the mortality rate associated with COVID-19.
Ipsen appoints new board director
Coiled Therapeutics completes enrolment in two AO-252 formulation cohorts
MaaT Pharma outlines potential Phase 3 development plan for MaaT013 after CHMP negative opinion
Kemp Proteins partners with NeuImmune to advance precision protein production
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
ProBio and Kun Tuo collaborate to deliver integrated CDMO-CRO solutions for advanced therapies
Myosin Therapeutics chosen for 2026-2027 NCI Investor Initiatives Showcase
Sobi and Innate confirm strategic partnership
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease